DurAVR™ THV EU-EFS

Inclusion Criteria: 1. Symptomatic, severe native aortic stenosis or severe degeneration of surgically implanted aortic bioprosthetic valve in subjects 18 years or older. 2. Requires aortic valve replacement and is indicated for TAVR as determined by the Heart Team 3. Eligible for transfemoral delivery of the DurAVR™ THV 4. Anatomy appropriate to accommodate safe placement of DurAVR™ THV 5. Understands the study requirements and the treatment procedures and provides written informed consent 6. Subject agrees to complete all required scheduled follow-up visits. Exclusion Criteria: 1. Anatomy precluding safe placement of DurAVR™ THV 2. Pre-existing prosthetic mitral or tricuspid valve 3. Unicuspid, bicuspid or non-calcified aortic valve 4. Severe mitral or severe tricuspid regurgitation requiring intervention 5. Moderate to severe mitral stenosis 6. Hypertrophic obstructive cardiomyopathy 7. Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment 8. Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment 9. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure 10. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA) 11. End-stage renal disease requiring chronic dialysis or creatinine clearance \< 20 cc/min 12. GI bleeding within the past 3 months 13. Ongoing sepsis (including active endocarditis) or endocarditis in the last 3 months 14. Life expectancy \< 12 months due to associated non-cardiac co-morbid conditions